[
  {
    "ts": null,
    "headline": "If I Could Only Buy 2 High Dividend Yield Companies In November 2024: Both Yield Above 6%",
    "summary": "I have selected Pfizer and Verizon as my top two high dividend yield companies to invest in for November 2024. Click here to read why.",
    "url": "https://finnhub.io/api/news?id=2c27f76c1a4473b68a35deb23938849d0cdc0e57de84b554bb3fc7a67d64297d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732039200,
      "headline": "If I Could Only Buy 2 High Dividend Yield Companies In November 2024: Both Yield Above 6%",
      "id": 131493816,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1160839858/image_1160839858.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "I have selected Pfizer and Verizon as my top two high dividend yield companies to invest in for November 2024. Click here to read why.",
      "url": "https://finnhub.io/api/news?id=2c27f76c1a4473b68a35deb23938849d0cdc0e57de84b554bb3fc7a67d64297d"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson stock underperforms Tuesday when compared to competitors",
    "summary": "Johnson & Johnson stock underperforms Tuesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=6cdfe8bb1e2da5dbc25449bb961a804079bebcf8c54dd425ea94925cf7323896",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732033860,
      "headline": "Johnson & Johnson stock underperforms Tuesday when compared to competitors",
      "id": 131505980,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "Johnson & Johnson stock underperforms Tuesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=6cdfe8bb1e2da5dbc25449bb961a804079bebcf8c54dd425ea94925cf7323896"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson to showcase strength of its broad hematology portfolio and pipeline at the 2024 American Society of Hematology Annual Meeting",
    "summary": "Johnson & Johnson (NYSE:JNJ) announced today more than 90 abstracts featuring data from the Company's differentiated blood cancer portfolio and pipeline will be presented at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego from December 7-10. Clinical trial and real-world data will highlight the Company's broad and expanding portfolio of hematologic therapies, deepening its leadership in novel approaches to treat multiple myeloma as well as myeloid and B-cell malignancie",
    "url": "https://finnhub.io/api/news?id=0cd5c3e248f1f416e965afe67b63a83f566c3fae8d8b2cc6212d620460e088a4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732024920,
      "headline": "Johnson & Johnson to showcase strength of its broad hematology portfolio and pipeline at the 2024 American Society of Hematology Annual Meeting",
      "id": 131484131,
      "image": "https://media.zenfs.com/en/prnewswire.com/388c9d27a537cc3a83771c29d6c3a86b",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) announced today more than 90 abstracts featuring data from the Company's differentiated blood cancer portfolio and pipeline will be presented at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego from December 7-10. Clinical trial and real-world data will highlight the Company's broad and expanding portfolio of hematologic therapies, deepening its leadership in novel approaches to treat multiple myeloma as well as myeloid and B-cell malignancie",
      "url": "https://finnhub.io/api/news?id=0cd5c3e248f1f416e965afe67b63a83f566c3fae8d8b2cc6212d620460e088a4"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know",
    "summary": "Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.",
    "url": "https://finnhub.io/api/news?id=63d5173fa588ffa22dd9947d1e44724bca1ebdb05ff198b62595187a98e92c42",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732024817,
      "headline": "Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know",
      "id": 131484134,
      "image": "https://media.zenfs.com/en/zacks.com/2a50596f066181e48e4ae0ad6be00462",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.",
      "url": "https://finnhub.io/api/news?id=63d5173fa588ffa22dd9947d1e44724bca1ebdb05ff198b62595187a98e92c42"
    }
  },
  {
    "ts": null,
    "headline": "How I Repurposed My Late Father's Trust Account",
    "summary": "I restructured my father's Trust for better diversification and risk reduction. See why I reduced Health Care and Consumer stocks and shifted to new sectors.",
    "url": "https://finnhub.io/api/news?id=15b16fcae92f6698a79d30b640741803fef606dc53bf6706d6ae2323f9f9d2f9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732019685,
      "headline": "How I Repurposed My Late Father's Trust Account",
      "id": 131478623,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/175431947/image_175431947.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "I restructured my father's Trust for better diversification and risk reduction. See why I reduced Health Care and Consumer stocks and shifted to new sectors.",
      "url": "https://finnhub.io/api/news?id=15b16fcae92f6698a79d30b640741803fef606dc53bf6706d6ae2323f9f9d2f9"
    }
  },
  {
    "ts": null,
    "headline": "J&J pill clears skin in two late-stage psoriasis studies",
    "summary": "The drug, called icotrokinra and developed together with Protagonist Therapeutics, is an oral peptide designed to tamp down the inflammation involved in psoriasis and other immune diseases.",
    "url": "https://finnhub.io/api/news?id=6a1d10c386cec28aad25d54e139c445db3cc57d097a99732c04029abd344283a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732015440,
      "headline": "J&J pill clears skin in two late-stage psoriasis studies",
      "id": 131484137,
      "image": "https://imgproxy.divecdn.com/6JgGj709WMZ18gsPV4CteAPEmoVLeB7XNOXakxp9pkA/g:ce/rs:fit:770:435/bG9jYWw6Ly8vZGl2ZWltYWdlL0dldHR5SW1hZ2VzLTE3NDEzMDg1MTguanBn.webp",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The drug, called icotrokinra and developed together with Protagonist Therapeutics, is an oral peptide designed to tamp down the inflammation involved in psoriasis and other immune diseases.",
      "url": "https://finnhub.io/api/news?id=6a1d10c386cec28aad25d54e139c445db3cc57d097a99732c04029abd344283a"
    }
  },
  {
    "ts": null,
    "headline": "J&J: to present its advances in hematology",
    "summary": "Johnson & Johnson will present more than 90 abstracts covering data from its portfolio and sib pipeline in the treatment of blood cancers at the 66th annual meeting of the American Society of...",
    "url": "https://finnhub.io/api/news?id=7e650dc5ccbf9ded6f61a9ea9aa1d51eeabf339a3dab5fda1a8ba574d8a9a81e",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732015392,
      "headline": "J&J: to present its advances in hematology",
      "id": 131473842,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Johnson & Johnson will present more than 90 abstracts covering data from its portfolio and sib pipeline in the treatment of blood cancers at the 66th annual meeting of the American Society of...",
      "url": "https://finnhub.io/api/news?id=7e650dc5ccbf9ded6f61a9ea9aa1d51eeabf339a3dab5fda1a8ba574d8a9a81e"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson: Policy Uncertainty Elevated, But Shares Remain Inexpensive",
    "summary": "Johnson & Johnson faces uncertainty with speculation about RFK Jr. at HHS. Learn why JNJ stock remains a buy despite political risks and soft trends.",
    "url": "https://finnhub.io/api/news?id=6ed15bc770f371811b235648ff46d6f3b365b232c3416cd111b32445709b010f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732013446,
      "headline": "Johnson & Johnson: Policy Uncertainty Elevated, But Shares Remain Inexpensive",
      "id": 131472220,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1180491673/image_1180491673.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Johnson & Johnson faces uncertainty with speculation about RFK Jr. at HHS. Learn why JNJ stock remains a buy despite political risks and soft trends.",
      "url": "https://finnhub.io/api/news?id=6ed15bc770f371811b235648ff46d6f3b365b232c3416cd111b32445709b010f"
    }
  },
  {
    "ts": null,
    "headline": "Walt Disney, Sherwin-Williams Co. share losses lead Dow's nearly 200-point fall",
    "summary": "Walt Disney, Sherwin-Williams Co. share losses lead Dow's nearly 200-point fall",
    "url": "https://finnhub.io/api/news?id=13c780ea8ad94fc0adb9fda9d65fba8d177298cde4b9d6359d9e1f63d601db91",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732013160,
      "headline": "Walt Disney, Sherwin-Williams Co. share losses lead Dow's nearly 200-point fall",
      "id": 131472873,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "Walt Disney, Sherwin-Williams Co. share losses lead Dow's nearly 200-point fall",
      "url": "https://finnhub.io/api/news?id=13c780ea8ad94fc0adb9fda9d65fba8d177298cde4b9d6359d9e1f63d601db91"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson reports topline outcomes from trial of icotrokinra for psoriasis",
    "summary": "The trial met its co-primary endpoints at week 16, with skin clearance observed compared to placebo.",
    "url": "https://finnhub.io/api/news?id=5028e6a8033ecaacfe276cd3b8413ffad1b78912cecc0214db3b41ff87c77c28",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732011723,
      "headline": "Johnson & Johnson reports topline outcomes from trial of icotrokinra for psoriasis",
      "id": 131484140,
      "image": "https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/11/CTA-1-JJ-Psoriasis-Shutterstock_2167752173.jpg",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The trial met its co-primary endpoints at week 16, with skin clearance observed compared to placebo.",
      "url": "https://finnhub.io/api/news?id=5028e6a8033ecaacfe276cd3b8413ffad1b78912cecc0214db3b41ff87c77c28"
    }
  },
  {
    "ts": null,
    "headline": "Home Depot, Walt Disney share losses lead Dow's 325-point fall",
    "summary": "Home Depot, Walt Disney share losses lead Dow's 325-point fall",
    "url": "https://finnhub.io/api/news?id=ad5aa5a5872cf8f36b7fc8b1a261239e978405e9019819e876d3c4cefb8d32ee",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732009500,
      "headline": "Home Depot, Walt Disney share losses lead Dow's 325-point fall",
      "id": 131473090,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "Home Depot, Walt Disney share losses lead Dow's 325-point fall",
      "url": "https://finnhub.io/api/news?id=ad5aa5a5872cf8f36b7fc8b1a261239e978405e9019819e876d3c4cefb8d32ee"
    }
  },
  {
    "ts": null,
    "headline": "IXJ: Healthcare Sector Dashboard For November",
    "summary": "November dashboard shows the healthcare sector is overvalued by 18% relative to 11-yr averages; pharma/biotech and healthcare equipment, the most overpriced.",
    "url": "https://finnhub.io/api/news?id=17b2ae374f72b898be1e13a220d648b578b5b9ae1db05e9f4365ec93e3d05504",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732007700,
      "headline": "IXJ: Healthcare Sector Dashboard For November",
      "id": 131471159,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/688000635/image_688000635.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "November dashboard shows the healthcare sector is overvalued by 18% relative to 11-yr averages; pharma/biotech and healthcare equipment, the most overpriced.",
      "url": "https://finnhub.io/api/news?id=17b2ae374f72b898be1e13a220d648b578b5b9ae1db05e9f4365ec93e3d05504"
    }
  },
  {
    "ts": null,
    "headline": "J&J: positive results for icotrokinra in psoriasis",
    "summary": "Johnson & Johnson announces positive results from a Phase 3 study of icotrokinra for patients aged 12 and over with moderate to severe plaque psoriasis. The study met its primary objectives, with...",
    "url": "https://finnhub.io/api/news?id=c126b1708c123e6fbf2c10a19ca4a91c50528eca403c3999b5f143bc40cbb4f2",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731993927,
      "headline": "J&J: positive results for icotrokinra in psoriasis",
      "id": 131467194,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Johnson & Johnson announces positive results from a Phase 3 study of icotrokinra for patients aged 12 and over with moderate to severe plaque psoriasis. The study met its primary objectives, with...",
      "url": "https://finnhub.io/api/news?id=c126b1708c123e6fbf2c10a19ca4a91c50528eca403c3999b5f143bc40cbb4f2"
    }
  },
  {
    "ts": null,
    "headline": "Fidelity Select Health Care Portfolio Q3 2024 Fund Review",
    "summary": "For Q3 2024, the Fidelity Select Health Care Portfolio fund gained 9.48%, outperforming the MSCI sector index. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=f19c540ed18a1c2f912d6ff2c1c5be2a7f351bca6a9d716c8a57b31d84916382",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731993000,
      "headline": "Fidelity Select Health Care Portfolio Q3 2024 Fund Review",
      "id": 131467028,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1849023174/image_1849023174.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "For Q3 2024, the Fidelity Select Health Care Portfolio fund gained 9.48%, outperforming the MSCI sector index. Click here to read the full commentary.",
      "url": "https://finnhub.io/api/news?id=f19c540ed18a1c2f912d6ff2c1c5be2a7f351bca6a9d716c8a57b31d84916382"
    }
  }
]